EDITORS' DESK

  • New U.S And Canadian Facilities Boosting Biologics Capacity
    New U.S And Canadian Facilities Boosting Biologics Capacity

    Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.

A Glimpse Into Thailand’s Ongoing Life Sciences Transformation

During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.

What Thailand Revealed About U.S. Pharma R&D

A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.

Top 5 Biosimilar Developments Of 2016

In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

Are You The Future of Pharmaceutical Development?

Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.

More From Our Editors

GUEST CONTRIBUTORS

  • Why Data Integrity Is Impossible Without A Quality Culture
    Why Data Integrity Is Impossible Without A Quality Culture

    Quite a bit has been written about data integrity in recent years, and an embedded, effective quality culture remains a critical success factor for fully realizing strong data integrity. In recently published guidance on data integrity, the FDA goes so far as to state very directly that “it is the role of management with executive responsibility to create a quality culture where employees understand that data integrity is an organizational core value and employees are encouraged to identify and promptly report data integrity issues.”

  • Reimagining Quality Operations In The Life Sciences
    Reimagining Quality Operations In The Life Sciences

    This is the third of three articles focusing on an effort to address what appear to be systemic issues across quality departments, informed by a multinational group comprising chief quality officers (CQOs) from pharma, device, animal health, and consumer goods companies. It will examine how to achieve cross-functional ownership of quality and the efforts of the CQO team to build quality for the 21st century, including exploring the creation of formal degree programs in quality.

  • How Technology Will Reshape The Future Of Aseptic Processing
    How Technology Will Reshape The Future Of Aseptic Processing

    Using new and existing technologies to improve aseptic processing manufacturing may provide the need and opportunity for new approaches to process control and monitoring. In some cases, improvements to these approaches will require the use of existing technology. In other cases, they will be required to support the implementation and use of new technology.

  • How To Write An Effective Validation Master Plan

    A validation master plan (VMP) outlines the principles involved in the qualification of a facility, defining the areas and systems to be validated, and provides a written program for achieving and maintaining a qualified facility. Master plans are written to assist an organization with validation strategies or to provide control over a specific process.

  • The Top 3 Forms Of Operational Overcomplexity In Pharma Manufacturing — And How To Simplify Them

    We like simplicity. Yet in pharmaceutical operations we have become very good at making things more complex than they need to be.  This article illustrates a few areas where companies tend to make matters worse and highlights areas where both industry and regulatory agency leaders should push back and focus on simplification.

More From Guest Contributors

PHARMA ONLINE WHITE PAPERS

More Pharma Onine White Papers

INDUSTRY INSIGHTS

More Industry Insights

PHARMA INDUSTRY EVENTS

12th Annual Oncoloy Market Access Strategy Summit February 20 - 21, 2019
San Francisco, CA
SMi's 3rd Annual 3D Cell Culture February 20 - 21, 2019
London
SMi’s 3rd Annual 3D Cell Culture Conference February 20 - 21, 2019
Greater London
29th International Conference on Neuroscience February 20 - 21, 2019
Sydney
More Industry Events

TRAINING COURSES

More Upcoming Courses